A missense polymorphism in ATF6 gene is associated with susceptibility to hepatocellular carcinoma probably by altering ATF6 level

International Journal of Cancer

Volumn 135, Issue 1, 2014, Pages 61-68

  Wu, Xiaopan ^a   Xin, Zhenhui ^a   Zhang, Wei ^b   Zheng, Sujun ^c   Wu, Jia ^a   Chen, Kangmei ^a   Wang, Huifen ^d   Zhu, Xilin ^a   Li, Zhuo ^c   Duan, Zhongping ^c   Li, Hui ^a   Liu, Ying ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d BEIJING 302 HOSPITAL   (China)

Author keywords

ATF6; hepatocellular carcinoma; luciferase assay; real time PCR; single nucleotide polymorphisms

Indexed keywords

ATF6; HEPATOCELLULAR CARCINOMA; LUCIFERASE ASSAY; REAL-TIME PCR; SINGLE NUCLEOTIDE POLYMORPHISMS;

ACTIVATING TRANSCRIPTION FACTOR 6; ADULT; CARCINOMA, HEPATOCELLULAR; CHINA; DISEASE PROGRESSION; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION, MISSENSE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84899445472     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28649     Document Type: Article

References (24)

1. Bosch FX, Ribes J, Cleries R, et al. Epidemiology of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 191-211, v.
2. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004; 127: S5-S16.
3. Chen CJ, Chen DS,. Interaction of hepatitis B virus, chemical carcinogen, and genetic susceptibility: multistage hepatocarcinogenesis with multifactorial etiology. Hepatology 2002; 36: 1046-9.
4. Clifford RJ, Zhang J, Meerzaman DM, et al. Genetic variations at loci involved in the immune response are risk factors for hepatocellular carcinoma. Hepatology 2010; 52: 2034-43.
5. Long XD, Ma Y, Zhou YF, et al. Polymorphism in xeroderma pigmentosum complementation group C codon 939 and aflatoxin B1-related hepatocellular carcinoma in the Guangxi population. Hepatology 2010; 52: 1301-9.
6. Deng G, Zhou G, Zhang R, et al. Regulatory polymorphisms in the promoter of CXCL10 gene and disease progression in male hepatitis B virus carriers. Gastroenterology 2008; 134: 716-26.
7. Kumar V, Kato N, Urabe Y, et al. Genome-wide association study identifies a susceptibility locus for HCV-induced hepatocellular carcinoma. Nat Genet 2011; 43: 455-8.
8. Zhang H, Zhai Y, Hu Z, et al. Genome-wide association study identifies 1p36.22 as a new susceptibility locus for hepatocellular carcinoma in chronic hepatitis B virus carriers. Nat Genet 2010; 42: 755-8.
9. Chan KY, Wong CM, Kwan JS, Lee JM, Cheung KW, Yuen MF, Lai CL, Poon RT, Sham PC, Ng IO,. Genome-wide association study of hepatocellular carcinoma in Southern Chinese patients with chronic hepatitis B virus infection. PLoS One 2011; 6: e28798.
10. Li S, Qian J, Yang Y, et al. GWAS identifies novel susceptibility loci on 6p21.32 and 21q21.3 for hepatocellular carcinoma in chronic hepatitis B virus carriers. PLoS Genet 2012; 8: e1002791.
11. Jiang DK, Sun J, Cao G, et al. Genetic variants in STAT4 and HLA-DQ genes confer risk of hepatitis B virus-related hepatocellular carcinoma. Nat Genet 2013; 45: 72-5.
12. Fels DR, Koumenis C,. The PERK/eIF2alpha/ATF4 module of the UPR in hypoxia resistance and tumor growth. Cancer Biol Ther 2006; 5: 723-8.
13. Ma Y, Hendershot LM,. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer 2004; 4: 966-77.
14. Namba T, Ishihara T, Tanaka K, et al. Transcriptional activation of ATF6 by endoplasmic reticulum stressors. Biochem Biophys Res Commun 2007; 355: 543-8.
15. Kaneko M, Nomura Y,. ER signaling in unfolded protein response. Life Sci 2003; 74: 199-205.
16. So AY, de la Fuente E, Walter P, et al. The unfolded protein response during prostate cancer development. Cancer Metastasis Rev 2009; 28: 219-23.
17. Shuda M, Kondoh N, Imazeki N, et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol 2003; 38: 605-14.
18. Chu WS, Das SK, Wang H, et al. Activating transcription factor 6 (ATF6) sequence polymorphisms in type 2 diabetes and pre-diabetic traits. Diabetes 2007; 56: 856-62.
19. Meex SJ, Weissglas-Volkov D, van der Kallen CJ, et al. The ATF6-Met[67]Val substitution is associated with increased plasma cholesterol levels. Arterioscler Thromb Vasc Biol 2009; 29: 1322-7.
20. Fougeray S, Loriot MA, Nicaud V, et al. Increased body mass index after kidney transplantation in activating transcription factor 6 single polymorphism gene carriers. Transplant Proc 2011; 43: 3418-22.
21. Livak KJ, Schmittgen TD,. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001; 25: 402-8.
22. Shi YY, He L,. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-8.
23. Suh DH, Kim MK, Kim HS, et al. Unfolded protein response to autophagy as a promising druggable target for anticancer therapy. Ann N Y Acad Sci 2012; 1271: 20-32.
24. Shen J, Chen X, Hendershot L, et al. ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals. Dev Cell 2002; 3: 99-111.